ArticleAMIA ... Annual Symposium proceedings. AMIA Symposium2019
Assessing the Validity of a
Article in AMIA ... Annual Symposium proceedings. AMIA Symposium, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A review of research on eligibility criteria for clinical trials.Clinical and experimental medicine · 2023Review
- Pediatric and adult asthma clinical phenotypes: a real world, big data study based on acute exacerbations.The Journal of asthma : official journal of the Association for the Care of Asthma · 2023Article
- Machine learning enabled subgroup analysis with real-world data to inform clinical trial eligibility criteria design.Scientific reports · 2023Article
- Liquid biopsy for early detection and therapeutic monitoring of hepatocellular carcinoma.Journal of liver cancer · 2022Review
- Simulating Colorectal Cancer Trials Using Real-World Data.JCO clinical cancer informatics · 2022Article
- Multisite learning of high-dimensional heterogeneous data with applications to opioid use disorder study of 15,000 patients across 5 clinical sites.Scientific reports · 2022Article
- Deep propensity network using a sparse autoencoder for estimation of treatment effects.Journal of the American Medical Informatics Association : JAMIA · 2021Article
- Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease.NPJ digital medicine · 2021Article
- Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Existing trials had not taken enough consideration of their population representativeness, which can lower the effectiveness when the treatment is applied in real-world clinical practice. We analyzed the eligibility criteria of Bevacizumab colorectal cancer treatment trials, assessed their a priori generalizability, and examined how it affects patient outcomes when applied in real-world clinical settings. To do so, we extracted patient-level data from a large collection of electronic health records (EHRs) from the OneFlorida consortium. We built a zero-inflated negative binomial model using a composite patient-trial generalizability (cPTG) score to predict patients' clinical outcomes (i.e., number of serious adverse events, [SAEs]). Our study results provide a body of evidence that 1) the cPTG scores can predict patient outcomes; and 2) patients who are more similar to the study population in the trials that were used to develop the treatment will have a significantly lower possibility to experience serious adverse events.
Indexed as
Identifiers
32308907PMC7153072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.